GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Glenmark Pharmaceuticals Ltd (BOM:532296) » Definitions » 10-Year RORE %

Glenmark Pharmaceuticals (BOM:532296) 10-Year RORE % : -37.06% (As of Jun. 2024)


View and export this data going back to 2000. Start your Free Trial

What is Glenmark Pharmaceuticals 10-Year RORE %?

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. Glenmark Pharmaceuticals's 10-Year RORE % for the quarter that ended in Jun. 2024 was -37.06%.

The industry rank for Glenmark Pharmaceuticals's 10-Year RORE % or its related term are showing as below:

BOM:532296's 10-Year RORE % is ranked worse than
89.68% of 630 companies
in the Drug Manufacturers industry
Industry Median: 5.89 vs BOM:532296: -37.06

Glenmark Pharmaceuticals 10-Year RORE % Historical Data

The historical data trend for Glenmark Pharmaceuticals's 10-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Glenmark Pharmaceuticals 10-Year RORE % Chart

Glenmark Pharmaceuticals Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
10-Year RORE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.84 10.43 4.11 -3.92 -42.18

Glenmark Pharmaceuticals Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
10-Year RORE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -5.39 -10.98 -20.68 -42.18 -37.06

Competitive Comparison of Glenmark Pharmaceuticals's 10-Year RORE %

For the Drug Manufacturers - Specialty & Generic subindustry, Glenmark Pharmaceuticals's 10-Year RORE %, along with its competitors' market caps and 10-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Glenmark Pharmaceuticals's 10-Year RORE % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Glenmark Pharmaceuticals's 10-Year RORE % distribution charts can be found below:

* The bar in red indicates where Glenmark Pharmaceuticals's 10-Year RORE % falls into.



Glenmark Pharmaceuticals 10-Year RORE % Calculation

Glenmark Pharmaceuticals's 10-Year RORE % for the quarter that ended in Jun. 2024 is calculated as:

10-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 10-year -Cumulative Dividends per Share for 10-year )
=( -46.47-17.62 )/( 194.94-22 )
=-64.09/172.94
=-37.06 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 10-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Jun. 2024 and 10-year before.


Glenmark Pharmaceuticals  (BOM:532296) 10-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 10-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.


Glenmark Pharmaceuticals 10-Year RORE % Related Terms

Thank you for viewing the detailed overview of Glenmark Pharmaceuticals's 10-Year RORE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Glenmark Pharmaceuticals Business Description

Traded in Other Exchanges
Address
Glenmark House, B. D. Sawant Marg, Chakala, Off Western Express Highway, Andheri (East), Mumbai, IND, 400099
Glenmark Pharmaceuticals Ltd is a specialty and generic drug manufacturing company. The company's research and development activity is focused on generating intellectual property assets that will help address unmet medical needs. Glenmark's product categories include novel molecular entities, formulations, and API products. The company considers merger and acquisition investment to be a potential component for expanding its research, development, manufacturing, and marketing capabilities.

Glenmark Pharmaceuticals Headlines

No Headlines